Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.
- Sponsor
- Dong-A ST Co., Ltd.
- Study ID
- NCT04326166
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Evogliptin — DRUGEvogliptin
- Evogliptin — DRUGEvogliptin
- Metformin and Evogliptin — DRUGMetformin and Evogliptin
Study Details
Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes
Key Dates
- First listed
- Mar 30, 2020
- Start date
- Mar 25, 2020
- Status verified
- Mar 2020
- Primary completion
- Jul 31, 2021
- Completion
- Jul 31, 2021
Study Design
- Enrollment
- 1,971 participants (estimated)
Arms
- Arm: Group APatients who receive Double therapy or Insulin
- Arm: Group BPatients who receive DPP-4 inhibitor
- Arm: Group CDrug-naïve patients
Primary Outcome Measure
Change in HbA1c [ Time Frame: at 12 weeks ]
Central Contacts
- Jongchul Won, M.D., Ph.D.+82-2-950-8860
Related Studies
- An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)Enrolling By Invitation · Novo Nordisk A/S · Morgantown, West Virginia
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.PHASE2 · Enrolling By Invitation · Columbia University · New York, New York
- Blood Markers of Early Pancreas CancerRecruiting · University of Nebraska · Omaha, Nebraska